Novel targets in non-small cell lung cancer: ROS1 and RET fusions

Oncologist

Volumn 18, Issue 7, 2013, Pages 865-875

  Gainor, Justin F ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Fusion oncogenes; Non small cell lung cancer; RET; ROS1; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; ASP 3026; AT 13387; CABOZANTINIB; CD74 ANTIGEN; CRIZOTINIB; GEFITINIB; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN; ROS1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CHROMOSOME REARRANGEMENT; DIMERIZATION; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE RET; ONCOGENE ROS1; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; GENE TRANSLOCATION; GENETICS; ISOLATION AND PURIFICATION; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; TRANSLOCATION, GENETIC;

EID: 84880664490     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0095     Document Type: Article

References (97)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
3. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
4. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-245.
5. Kaye FJ. Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther 2009;8: 1399-1408.
6. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007;448:561-566.
7. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with nonsmall-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
8. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
9. Birchmeier C, Birnbaum D, Waitches G et al. Characterization of an activated human ros gene. Mol Cell Biol 1986;6:3109-3116.
10. Nagarajan L, Louie E, Tsujimoto Y et al. The hu-man c-ros gene (ROS) is located at chromosome region 6q16-6q22. Proc Natl Acad Sci USA 1986;83: 6568-6572.
11. Matsushime H, Wang LH, Shibuya M. Humancros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 1986;6:3000-3004.
12. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009; 1795:37-52.
13. Sonnenberg E, Gödecke A, Walter B et al. Transient and locally restricted expression of the ros1 protooncogene during mouse development. EMBO J 1991;10:3693-3702.
14. Tessarollo L, Nagarajan L, Parada LF. C-ros: The vertebrate homolog of the sevenless tyrosine kinase receptor is tightly regulated during organogenesis in mouse embryonic development. Development 1992;115:11-20.
15. Sonnenberg-Riethmacher E, Walter B, Riethmacher D et al. The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev 1996;10: 1184-1193.
16. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 1987;84: 9270-9274.
17. Sharma S, Birchmeier C, Nikawa J et al. Characterization of the ros1-gene products expressed in human glioblastoma cell lines. Oncogene Res 1989; 5:91-100.
18. Charest A, Lane K, McMahon K et al. Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J Biol Chem 2001;276:29456-29465.
19. Charest A, Lane K, McMahon K et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71.
20. Charest A, Kheifets V, Park J et al. Oncogenic targeting ofanactivated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci USA 2003;100:916-921.
21. Gu TL, Deng X, Huang F et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6: e15640.
22. Birch AH, Arcand SL, Oros KK et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 2011; 6:e28250.
23. Lee J, Lee SE, Kang SY et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 2013;119:1627-1635.
24. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
25. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870.
26. Li C, Fang R, Sun Y et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011;6: e28204.
27. Davies KD, Le AT, Theodoro MF et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-4579.
28. Rimkunas VM, Crosby K, Kelly M et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIGROS1 fusion. Clin Cancer Res 2012;18:4449-4457.
29. Arai Y, Totoki Y, Takahashi H et al. Mouse model for ROS1-rearranged lung cancer. PLoS One 2013;8:e56010.
30. Govindan R, Ding L, Griffith M et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
31. Seo JS, Ju YS, Lee WC et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-2119.
32. Suehara Y, Arcila M, Wang L et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensivem RNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-6608.
33. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer Nat Med 2012;18: 378-381.
34. Yoshida A, Kohno T, Tsuta K et al. ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-562.
35. Jun HJ, Johnson H, Bronson RT et al. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 2012;72:3764-3774.
36. Charest A, Wilker EW, McLaughlin ME et al. ROS fusion tyrosine kinase activates a SH2 domaincontaining phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 2006; 66:7473-7481.
37. El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: A new potential target for anticancer drugs. Med Res Rev 2011;31:794-818.
38. Ju YS, Lee WC, Shin JY et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-445.
39. Chin LP, Soo RA, Soong R et al. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 2012;7:1625-1630.
40. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011;9:1335-1341.
41. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174: 661-670.
42. Stumpfova M, Jänne PA. Zeroing inon ROS1 rearrangements in non-small cell lung cancer. Clin Cancer Res 2012;18:4222-4224.
43. Jänne PA, Meyerson M. ROS1 rearrangements in lung cancer:Anewgenomicsubset of lungadenocarcinoma. J Clin Oncol 2012;30:878-879.
44. McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-3395.
45. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012;7:1086-1090.
46. Shaw A, Camidge D, Engelman J et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012;30(suppl):7508a.
47. Ou S, Camidge R, Engelman J et al. Clinical activity of crizotinib in patients with advanced nonsmall cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Ann Oncol 2012;23(suppl):2091a.
48. Proia D, Acquaviva J, Jiang Q et al. Preclinical activity of the HSP90 inhibitor, ganetespib, in ALKand ROS1-driven cancers. J Clin Oncol 2012; 30(suppl):3090a.
49. National Comprehensive Cancer Network. Non-small cell lung cancer (version 2.2013). Available at http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 28, 2013.
50. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-588.
51. Ishizaka Y, Itoh F, Tahira T et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989;4:1519-1521.
52. Wells SA, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009;15: 7119-7123.
53. Nakamura T, Ishizaka Y, Nagao M et al. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994;172:255-260.
54. Takahashi M, Buma Y, Iwamoto T et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-578.
55. Schuchardt A, D'Agati V, Larsson-Blomberg L et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994;367:380-383.
56. Pichel JG, Shen L, Sheng HZ et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996;382:73-76.
57. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380-393.
58. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16:5936-5941.
59. Trupp M, Arenas E, Fainzilber M et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996;381:785-789.
60. Durbec P, Marcos-Gutierrez CV, Kilkenny C et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789-793.
61. Jing S, Wen D, Yu Y et al. GDNF-induced activation of the ret protein tyrosine kinase ismediatedby GDNFR-alpha, a novel receptor for GDNF. Cell 1996; 85:1113-1124.
62. Ibáñez CF. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol 2013;5:a009134.
63. Edery P, Lyonnet S, Mulligan LM et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:378-380.
64. Romeo G, Ronchetto P, Luo Y et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:377-378.
65. Grieco M, Santoro M, Berlingieri MT et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563.
66. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006;155:645-653.
67. Bounacer A, Wicker R, Schlumberger M et al. Oncogenic rearrangements of the ret proto-oncogene in thyroid tumors induced after exposure to ionizing radiation. Biochimie 1997;79:619-623.
68. Ito T, Seyama T, Iwamoto KS et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994;344:259.
69. Hamatani K, Eguchi H, Ito R et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 2008;68: 7176-7182.
70. Drosten M, Pützer BM. Mechanisms of disease: Cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006;3:564-574.
71. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
72. Mulligan LM, Kwok JB, Healey CS et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363: 458-460.
73. Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579-1583.
74. Romei C, Elisei R, Pinchera A et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-1622.
75. Marsh DJ, Learoyd DL, Andrew SD et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996;44:249-257.
76. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18: 375-377.
77. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18: 382-384.
78. Li F, Feng Y, Fang R et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012;22:928-931.
79. Wang R, Hu H, Pan Y et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30: 4352-4359.
80. Yokota K, Sasaki H, Okuda K et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep 2012;28:1187-1192.
81. Sasaki H, Shimizu S, Tani Y et al. RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med 2012;1:68-75.
82. Cai W, Su C, Li X et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 2013;119:1486-1494.
83. Kim SC, Jung Y, Park J et al. Ahigh-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One 2013;8:e55596.
84. Chao BH, Briesewitz R, Villalona-Calero MA. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012;30:4439-4441.
85. Drilon A, Wang L, Hasanovic A et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013 [Epub ahead of print].
86. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-351.
87. Su AI, Cooke MP, Ching KA et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 2002;99:4465-4470.
88. Marotta V, Guerra A, Sapio MR et al. RET/PTC rearrangement in benignandmalignant thyroid diseases: A clinical standpoint. Eur J Endocrinol 2011; 165:499-507.
89. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, doubleblind phase III trial. J Clin Oncol 2012;30:134-141.
90. Schoffski P, Ellisei R, Muller S et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012;30(suppl):5508a.
91. Houvras Y. Completing the arc: Targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol 2012;30:200-202.
92. Matsubara D, Kanai Y, Ishikawa S et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad J Thorac Oncol 2012;7:1872-1876.
93. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656.
94. Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-1548.
95. Blumenschein GR, Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of singleagent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-4280.
96. Lee JS, Hirsh V, Park K et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-1121.
97. Gautschi O, Zander T, Keller FA et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013;8:e43-e44.